0
edits
No edit summary |
No edit summary |
||
Line 14: | Line 14: | ||
|} | |} | ||
{| class="wikitable" cellpadding="0" cellspacing="0" border="0 | {| class="wikitable" cellpadding="0" cellspacing="0" border="0" | ||
|- | |- | ||
|colspan="3"|Advantages and disadvantages of mechanical and bioprosthetic | |colspan="3"|'''Advantages and disadvantages of mechanical and bioprosthetic''' | ||
|- | |- | ||
! | ! | ||
Line 22: | Line 22: | ||
!Biological | !Biological | ||
|- | |- | ||
! | !valign="top"|Advantages | ||
|Durable | |valign="top"| | ||
*Durable | |||
| | | | ||
*No anticoagulation needed | *No anticoagulation needed | ||
Line 32: | Line 33: | ||
*Less risk of infection in the ring or edge flap | *Less risk of infection in the ring or edge flap | ||
*No pannus (tissue ingrowth) | *No pannus (tissue ingrowth) | ||
|- | |- | ||
! | !valign="top"|Disadvantages | ||
| | | | ||
*Anticoagulation needed | |||
*Any obstruction of the blood flow | *Any obstruction of the blood flow | ||
*Leakage (leakage backflow after valve closure, closure backflow flap for closure. | *Leakage (leakage backflow after valve closure, closure backflow flap for closure. | ||
Line 42: | Line 43: | ||
*Infection in ring or rim valve (endocarditis). | *Infection in ring or rim valve (endocarditis). | ||
*Pannus (tissue ingrowth) | *Pannus (tissue ingrowth) | ||
|Degeneration is 10-15 years | |valign="top"| | ||
*Degeneration is 10-15 years | |||
|- | |- | ||
|colspan="3"|'''NB: For all valve prostheses is indicated in some cases endocarditis prophylaxis.'''<cite>1</cite> | |||
|} | |} | ||
edits